← Eichor
Condition: Parkinson Disease Secondary Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Parkinson Disease Secondary

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Accelerated Temporal Interference Stimulation on Bilateral Subthalamic Nucleus for Parkinson's Disease and Secondary Par
NA · 1 location(s) · Ke Dong, MD · NCT07568067Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung C
Phase 3 · 225 location(s) · Merck Sharp & Dohme LLC · NCT06345729Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small C
Phase 3 · 220 location(s) · Merck Sharp & Dohme LLC · NCT06170788Abbott DBS Post-Market Study of Outcomes for Indications Over Time
Phase N/A · 48 location(s) · Abbott Medical Devices · NCT04071847Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Phase 1/Phase 2 · 47 location(s) · Merck Sharp & Dohme LLC · NCT06445972A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in
Phase 3 · 267 location(s) · Merck Sharp & Dohme LLC · NCT06841354Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care
NA · 1 location(s) · University Hospital, Lille · NCT04179695A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Tr
Phase 3 · 259 location(s) · Merck Sharp & Dohme LLC · NCT06312176KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 34 location(s) · Merck Sharp & Dohme LLC · NCT07252739A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · 155 location(s) · Merck Sharp & Dohme LLC · NCT07216703
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.